Citadel Advisors
ENTX icon

Citadel Advisors’s Entera Bio ENTX Stock Holding History

Citadel Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
+10,100
New +$12.6K ﹤0.01% 13426
2025
Q2 		– Sell
-100
Closed -$170 – 13178
2025
Q1 		$170 Buy
+100
New +$218 ﹤0.01% 14314
2024
Q4 		– Sell
-100
Closed -$190 – 14719
2024
Q3 		$190 Buy
+100
New +$177 ﹤0.01% 14078
2023
Q4 		– Sell
-100
Closed -$73 – 14504
2023
Q3 		$73 Buy
+100
New +$74 ﹤0.01% 14173
2023
Q2 		– Sell
-1,000
Closed -$1.16K – 14534
2023
Q1 		$1.16K Buy
1,000
+700
+233% +$699 ﹤0.01% 14351
2022
Q4 		$219 Buy
+300
New +$217 ﹤0.01% 14724
2022
Q1 		– Sell
-19,900
Closed -$56K – 13821
2021
Q4 		$56K Sell
19,900
-24,500
-55% -$91.8K ﹤0.01% 13182
2021
Q3 		$209K Sell
44,400
-46,400
-51% -$238K ﹤0.01% 11898
2021
Q2 		$543K Buy
+90,800
New +$336K ﹤0.01% 9890

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Citadel Advisors's ENTX Position: Q2 2026 in Review

Citadel Advisors reduced its Entera Bio (ENTX) stake by 84% in Q2 2026, selling an estimated $259K and leaving 38,804 shares worth $68.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12945.

Citadel Advisors first reported a position in ENTX in Q3 2020 and has held it in 16 quarters since. The position peaked at $402K in Q2 2021. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • Citadel Advisors held 38,804 shares of Entera Bio worth $68.7K as of Q2 2026.
  • Citadel Advisors sold 206,773 Entera Bio shares in Q2 2026, an estimated $259K.
  • Entera Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12945 holding.
  • Citadel Advisors first reported a position in Entera Bio in Q3 2020 and has held it in 16 quarters since.
  • Citadel Advisors's Entera Bio position peaked at $402K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.